Will FDA reject potential J&J blockbuster stroke drug? (Morning Read)

Current medical news from today, including Johnson & Johnson and Bayer blood thinner gets negative recommendation from FDA advisers, stem cell therapy to lessen heart failure gets trial in Europe, and $20 million for a modern doctor's office.

Current medical news and unique business news for anyone who cares about healthcare.

J&J blood thinner faces panel of tough critics. Johnson & Johnson and Bayer faced a huge blow when scientists at the FDA recommended that the regulation agency reject the companies’ blood thinner Xarelto. Analysts had predicted that Xarelto would generate sales of at least $1 billion as a more convenient substitute for warfarin, a stroke prevention drug that has been used for seven decades. The drug will be reviewed before a panel on Thursday.

Stem cell therapy for the heart. A single injection researchers say could prevent heart failure using stem cells from a healthy adult’s bone marrow has been cleared for its first European trial and could be available within five years. In studies, the treatment increased blood flow to damaged tissue to improved heart function.

The modern doctor’s office. A primary care practice in San Francisco and New York just closed a $20 million Series E round to implement new technology, but not the kind of technology you might think. One Medical Group is bringing its offices up-to-date so that patients can schedule appointments, request prescriptions, get lab results, ask questions, and view their medical records online. The practice even has its own iPhone app for scheduling appointments and addressing questions.

For entrepreneurship, from entrepreneurs. After eight roundtables with 1,000 entrepreneurs across the country, the Small Business Administration presented the White House with suggestions ways to reduce regulatory burdens for entrepreneurs, make it easier for them to find capital to grow, and help them find and retain great employees.

What makes a good EMR? Lack of usability is often the factor that inhibits EMR adoption. Here are five other characteristics to consider about EMR usability.

Shares0
Shares0